Advertisement
Survey Series
For Advertisers
|
|
||||
|
A Toll-like Take on Cancer Vaccines
The Scientist 2004, 18(11):34
|
||||
|
|
||||
|
CD8+ T-cell tolerance of tumors can block an aggressive immune response against cancer and may diminish the efficacy of therapeutic vaccines. But Yiping Yang, a Duke University immunologist, says he and his colleagues have found a way to overcome T-cell tolerance using the immune system's innate response to pathogens. Membrane-bound Toll-like receptors (TLRs) detect repetitive epitopes commonly found in pathogens. Activating these receptors can influence adaptive responses, including T cell-mediated immunity.
|
|
|||||||||
|
|||||||||
|
